SI
SI
discoversearch

Biotech / Medical
Spectral Medical Inc.
An SI Board Since October 2011
Posts SubjectMarks Bans Symbol
318 8 0 EDTXF
Emcee:  Sultan Type:  Unmoderated
Spectral is a Phase III company seeking U.S. FDA approval for its lead theranostics product for the treatment for severe sepsis and septic shock. Toraymyxin is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream. Directed by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis. Spectral's EUPHRATES trial is the world's first theranostics trial in the area of sepsis.

Toraymyxin has been approved for therapeutic use in Japan and Europe , and has been used safely and effectively in more than 80,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for Toraymyxin, and in November 2010, signed an exclusive distribution agreement for this product in Canada . More than 250,000 patients are diagnosed with severe sepsis and septic shock in North America each year, representing a greater than $1 billion market opportunity for Spectral. Spectral is listed on the Toronto Stock Exchange under the symbol SDI.

For further information please visit spectraldx.com
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
318AGM Presentation spectraldx.comSultan-June 4
317Spectral Provides Corporate Update TORONTO, May 30, 2018 (GLOBE NEWSWIRE) -- SSultan-May 30
316Odds are reasonable that we will collect IF we live long enough.. Another 12-24 Sultan-May 21
315New 52 week low. The towel being thrown in or something else? Do we still hJSB-May 21
314 Investor Update May 2018 spectraldx.comSultan-May 21
313 2012-02-29 2018-05-11 $EDT Spectral Medical Inc. Birch Hill Equity Partners ManSultan-May 12
312Spectral Announces First Quarter Results TORONTO, May 11, 2018 (GLOBE NEWSWIRE)Sultan-May 11
311Spectral Medical Completes $5.3 Million Financing TORONTO, April 23, 2018 (GLOBSultan-April 23
310Investor Update - New Presentation spectraldx.comSultan-April 5
309US Food and Drug Administration (FDA) provides communication to Spectral TORONTSultan-March 19
308Sepsis Detection Device Market to Be Driven by Rising Geriatric Population and HSultan1March 6
307Well hope so.. A number of news release last few months suggests we should expeSultan-February 25
306Our payday is coming soon.villiago-February 25
305 Active licence listing health-products.canada.caSultan-February 15
304Spectral Announces Health Canada Approval of Its Proprietary Stand-Alone Pump foSultan1February 15
303We are on the final stretch of the long marathon for Spectral and the share holdSultan-February 9
302Effects of polymyxin B hemoperfusion on hemodynamics and prognosis in septic shoSultan-February 9
301 [graphic] TORONTO, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Spectral Medical Inc., (villiago-February 1
300Spectral Medical Announces the Appointment of Chief Financial Officer TORONTO,Sultan-February 1
299Sepsis: the Achilles’ heel of health care statnews.comSultan-January 30
298This woman survived life-threatening sepsis, but what came next was even worse Sultan-January 30
297Sepsis costs Medicare $6 billion in 2015, more than any other discharge modernSultan-January 26
296Events are starting to unfold which should amount to a good payday for us eventuvilliago-12/22/2017
295CardioBrief: FDA's Gottlieb Preparing To Lower The Bar To Approval ShiftingSultan-12/21/2017
294Inpatient High-Risk Antibiotic Use Increases Subsequent Risk of Sepsis infectioSultan-12/20/2017
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2018 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.